Previous 10 | Next 10 |
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. 1x1s will be available for qualified investors The conference is completely complimentary to qualified investor...
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career o...
Odyssey Marine Exploration Inc. (OMEX) is expected to report for quarter end 2023-06-30 The Very Good Food Company Inc. (VGFCQ) is expected to report for quarter end 2023-06-30 SeaChange International Inc. (SEAC) is expected to report for Q1 2024 Allena Pharmaceuticals Inc. (ALNAQ) is...
QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 Amerityre Corp (AMTY) is expected to report for quarter end 2023-06-30 BYD Co - Class H (BYDDF) is expected to report for quarter end 2023-06-30 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2024 Ea...
Zovio Inc. (ZVOI) is expected to report for quarter end 2023-06-30 Sierra Grande Minerals Inc Ordinary Shares (SIERD) is expected to report for quarter end 2023-06-30 The Intergroup Corporation (INTG) is expected to report for Q1 2024 Fortescue Metals Group Ltd ADR (FSUGY) is expected...
Blue Water Biotech Inc. (BWV) is expected to report $-0.12 for Q2 2023 Lycos Energy Inc (MAAL) is expected to report for quarter end 2023-06-30 Esports Entertainment Group Inc. (GMBL) is expected to report $-2.92 for Q4 2023 SigmaTron International Inc. (SGMA) is expected to report fo...
American Bio Medica Corp. (ABMC) is expected to report for Q1 2024 Fonar Corporation (FONR) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q2 2023 QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 BIMI International Medical...
Novaccess Global Inc (XSNX) is expected to report for quarter end 2023-06-30
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH / ACCESSWIRE / July 27, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical compan...
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executive Officer Dr. Dwain K. Irvin will be participating in the National Brain Tumor Society's (NBTS) ...
News, Short Squeeze, Breakout and More Instantly...
CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance...
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company ...
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medi...